This model also shows that the muscle compartment responds to BoNT treatment by upregulating one of the muscle-specific ubiquitin ligases (Atrogin1), which is responsible for driving proteins destined for proteasome degradation and is active in many different pathologies characterized by muscle atrophy [79,80]. The gene discussed is FBXO32; the disease is muscle atrophy.